Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

July 30, 2020

NASDAQ US Health Care Biotechnology earnings 61 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Thanks, operator. Hello, everyone, and good morning. It's a pleasure to have you join Agios' Second Quarter 2020 Conference Call. Slides for today's call may be found in the Investors section at agios.com. Joining me today with prepared remarks are our Chief Executive Officer, Dr. Jackie Fouse; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of U.S. Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Our Chief Scientific Officer, Dr. Bruce Car, will be available for Q&A. Prior to beginning, I want to remind all of you that certain statements made on this call will contain forward-looking statements. Due to various risks, uncertainties and other factors, including those described in the risk factors section of our most recent Form 10-Q filed with the SEC and any other filings we may make with the SEC, actual events and results could differ materially from those expressed or implied by any forward-looking statements. With that, I'll hand the call over to Jackie.

Jacqualyn Fouse

executive
#2

Thank you, Holly. Hello, everyone, and I appreciate you being on the line for our call covering results from the second quarter of 2020. That quarter proved to be an extraordinarily productive and consequential period for Agios, since we achieved meaningful advancement throughout the company and completed a number of the essential goals we had laid out for 2020. What we did during Q2 reinforced the strategic priorities guiding us through the rest of the year and brought us nearer to realizing the vision we hold for 2025. It was 7 years back that we identified mitapivat, the first pyruvate kinase R activator. From that point onward, we have driven the science underpinning this mechanism, moved the Phase III program forward in pyruvate kinase deficiency, and turned into the initial company to show that activating wild-type PKR could deliver therapeutic value in additional hemolytic anemias, including thalassemia and sickle cell disease. During the last quarter, we reinforced our leadership position in this area even further and provided important updates that back our next stage of development for mitapivat. First off, we built convincing proof-of-concept for mitapivat in sickle cell disease, showing that PKR activation is capable of addressing chronic hemolytic anemia along with markers of sickling among these patients. Furthermore, at EHA, we shared data at a medical meeting for the first time concerning mitapivat in thalassemia, revealing sustained hemoglobin responses among patients with both beta-thalassemia and alpha-thalassemia. During May, the FDA gave us Orphan Drug Designation for that indication. Looking forward, we remain strongly dedicated to moving mitapivat ahead quickly across all 3 of these disease areas. The rest of 2020 is going to center on getting ready for top line data from the Phase III studies in PK deficiency, plus filing an NDA for mitapivat's first indication, along with the indication of pivotal programs in thalassemia and sickle cell disease during 2021. In June, we obtained $255 million in nonequity capital by selling our IDHIFA royalty and future milestones to Royalty Pharma, which will help finance these efforts. Beyond the progress we've made on the rare genetic disease portion of our business, we have kept pushing commercial execution for TIBSOVO and kept advancing our malignant hematology and solid tumor clinical programs. At ASCO and EHA, we delivered data that reinforced the value of IDH inhibitors in both of those areas; and during May, a manuscript came out in Lancet Oncology, bringing attention to data from the ClarIDHy Phase III study of TIBSOVO in cholangiocarcinoma. Because of that manuscript, the NCCN Guidelines received an update recommending treatment with TIBSOVO for patients who have advanced IDH1 mutant cholangiocarcinoma. We anticipate having overall survival data from the ClarIDHy study before long, which will back an expected sNDA submission during the first quarter of 2021. I take pride in our team for getting all of this excellent work done while still dealing with the difficulties and complications brought about by the continuing COVID-19 pandemic. Disruption to health care systems around the world keeps shifting as infection rates decline in certain regions while climbing in others, among them many states right here in the U.S. Both our organizational resiliency team and our clinical operations response team are still hard at work, continuously evaluating how COVID-19 affects each and every part of our business. Most of our staff are still working from home, but every lab employee who requires access to our Cambridge research labs is back on-site, operating under procedures meant to safeguard their health and well-being. Beyond that, where local rules and institutions have permitted it, a portion of our field team is once again able to meet with customers face to face. We keep reviewing further operating procedures that would enable a wider return to on-site work. I want to express my thanks to every single Agios employee for pressing forward with our programs for patients even as the pandemic weighs heavily on their personal and professional lives. Before handing the call to Chris, I feel it's important to recognize recent events, which have, yet again, laid bare the realities of racism and racial violence in our country. Here at Agios, we hold that matters of racial injustice deserve to be acknowledged and condemned, and we are committed to acting in allyship against this destructive force in our communities. Everyone at Agios believes in the value of diversity, and we are dedicated to making Agios a welcoming and diverse workplace where individuals of all backgrounds can thrive and contribute meaningfully to our mission on behalf of patients. Chris, let me turn it over to you.

Chris Bowden

executive
#3

Thanks, Jackie. I'll begin with mitapivat, which is our first-in-class PKR activator and is right now under evaluation in 3 separate hemolytic anemias. As Jackie pointed out, during the second quarter we hit key milestones for this program that back expanded clinical development in thalassemia as well as sickle cell disease. Our furthest-along effort sits in PK deficiency, where we've got 4 years of experience treating patients and could potentially deliver the first disease-modifying therapy. Earlier this year, we finished enrollment in our 2 Phase III trials, ACTIVATE and ACTIVATE-T. From the moment COVID-19 first appeared, we've concentrated on ensuring patients continue to receive study drug, and on capturing every piece of data regardless of whether someone is able to visit their trial site. That includes visits at home, telemedicine options, using local labs, and having drug delivered by courier. As the core phase of both studies comes to a close later this year, we're collaborating with our clinical trial sites worldwide to determine the schedule for finishing the steps required for database lock; our expectation remains that topline results for ACTIVATE and ACTIVATE-T will arrive somewhere in the window stretching from the close of 2020 through the midpoint of 2021. That timeline will get tighter based on how sure we are about getting into trial sites, which is hard to gauge while the pandemic continues. Our plan is to submit for approval with regulators in the U.S. and EU during the next year, and if all goes well, PK deficiency could reach the market in both regions by 2022. Now, on the Phase II trial of mitapivat for thalassemia: we finished bringing patients in earlier this year, with 20 enrolled. Then in June, during the virtual EHA meeting, we shared updated results covering 13 patients who could be assessed for efficacy. According to what the data revealed, among the 13 patients who could be evaluated, 12 saw their hemoglobin rise by at least 1 gram per deciliter between weeks 4 and 12 while on mitapivat. That included all 4 of the alpha-thalassemia patients — a population that has gone decades without any new therapeutic choices. On top of that, a sustained hemoglobin response was reached by 7 out of 8 beta-thalassemia patients across weeks 12 to 24. What we're concentrated on right now is moving mitapivat's development forward for these individuals as rapidly and effectively as we can. Before the year is over, our aim is to complete a comprehensive pivotal development strategy covering alpha- and beta-thalassemia, along with both transfusion-dependent and nontransfusion-dependent groups of patients, so that a pivotal program can begin in 2021. Moving on to sickle cell disease, we are working alongside Dr. Swee Lay Thein from the National Institutes of Health on a proof-of-concept trial involving mitapivat; back in June, we shared that clinical proof-of-concept had been achieved, drawing on an initial review of data from that trial. According to the data, 7 of 8 patients saw their hemoglobin go up across a dosing period of 6 to 8 weeks, and 5 of 8 patients reached an increase in hemoglobin of at least 1 gram per deciliter compared with baseline. During this trial, the safety profile we saw lined up with prior reports for mitapivat in PK deficiency patients, or with what you would expect in sickle cell disease. Now that we have these findings, we are acting quickly to gather input from regulators and advocacy organizations about our pivotal plan for sickle cell disease, which puts us in position to start the study at some point in 2021. Enrollment of patients into the Phase I sickle cell trial was paused on a temporary basis earlier in the year because of the COVID-19 pandemic, and the team is working hard to get that study reopened during the summer. Dr. Thein intends to enroll as many as 25 patients into this trial, and she will submit trial data for a presentation at the ASH meeting taking place in December. Because of that prior enrollment pause, we cannot yet say how many more patients beyond the 9 who formed the basis of our proof-of-concept evaluation will be part of that presentation. Now I'll turn to our malignant hematology programs, where our focus is on expanding geographically and by indication for TIBSOVO, our IDH1 inhibitor. First, in the EU, we have gotten our day-180 list of outstanding issues regarding the TIBSOVO filing for relapsed or refractory AML. Right now, we continue to expect a CHMP opinion before the year is over. When it comes to frontline AML, we've got two global Phase III combination studies now recruiting patients — AGILE and HOVON 150. These will allow us to broaden the frontline label for TIBSOVO so that it eventually includes use alongside azacitidine and 7 plus 3, respectively. In addition, we're bringing patients back into the myelodysplastic syndrome cohort of the Phase I TIBSOVO trial, which had been reopened, with the goal of generating the evidence required to support a potential U.S. regulatory submission. We expect to wrap up that additional enrollment at some point during 2021. Outside of these registration studies, we continue to investigate TIBSOVO and generate data on it in new combinations through investigator-initiated research. Results from one such effort — the IST combining venetoclax with TIBSOVO, with or without azacitidine, led by Dr. Courtney DiNardo and MD Anderson — those results were presented earlier this year at ASCO and EHA, showing the combo had an acceptable safety profile and worked well, with a composite complete response rate of 80% of patients. In May, we shared that the pandemic had caused site start-up efforts to slow down and led to enrollment disruptions at some trial locations. While we continue watching for new surges and how they impact trial sites, some regions have begun to stabilize. At this point, our guidance on enrollment for the AML and MDS studies remains unchanged. Switching over to solid tumors: last year, we announced favorable PFS findings from ClarIDHy, the Phase III study of TIBSOVO in patients with previously treated IDH1 mutant cholangiocarcinoma. Looking ahead to this quarter, we anticipate the study will yield mature overall survival results, and those would underpin a potential supplemental NDA submission. Based on how the data timeline is now coming together, we expect that sNDA to be filed in the first quarter of 2021 — a tighter timeframe than the one we previously communicated. Separately, enrollment continues across the rest of our solid tumor efforts: INDIGO, our Phase III study of vorasidenib, the brain-penetrant IDH inhibitor we're evaluating in low-grade glioma, along with the Phase I combination arms for AG-270 in non-small cell lung cancer and pancreatic cancer. As with the rest of our active studies, we're still watching how the pandemic affects site activation and enrollment efforts, and there's nothing new to share regarding prior guidance right now. On that note, I'll hand things to Darrin so he can walk through our commercial results for the second quarter.

Darrin Miles

executive
#4

Thanks, Chris. I'm happy to report that in 2020 our commercial group kept up its strong showing, posting $27.6 million in net sales for TIBSOVO during the second quarter, which represents a 22% rise over Q1. Even with the access limits tied to COVID-19, growth from one quarter to the next came from gains in new scripts as well as refills, with the biggest jumps occurring in the relapsed/refractory AML setting. On top of that, our prescriber base keeps getting bigger, up 15% across both the academic and community settings versus Q1. Market research keeps indicating that most physicians view TIBSOVO as standard of care in IDH1 mutant AML and as the top targeted treatment for newly diagnosed IDH1 mutant AML patients who are eligible for or receiving intensive therapy. Although it isn't something our promotional efforts center on, we keep seeing that roughly half of TIBSOVO use in the relapsed/refractory and frontline settings alike happens in combination, and most often that combination involves a hypomethylating agent. Our patient assistance program, myAgios, keeps running without interruption amid the COVID-19 pandemic as we stand by patients through these difficult times. As Jackie noted, in light of rising concerns tied to the pandemic, most of our field team has kept working from home since mid-March, even though some have started safely meeting their customers face-to-face once more as local guidelines and practices have permitted. We've had success keeping customers engaged through tools that make remote interactions possible. Given how we performed over the first half of the year, we reaffirm our full year 2020 U.S. TIBSOVO net sales guidance of $105 million to $115 million. I'll hand things over now to Andrew to go over our second quarter financials.

Andrew Hirsch

executive
#5

Appreciate that, Darrin. This morning's press release has our Q2 numbers in it, and I'll take you through them. More specifics will be in the 10-Q we file later today. Total revenue for the second quarter reached $37.3 million, which breaks down as $27.6 million of net sales from TIBSOVO, $6.4 million of collaboration revenue, and $3.3 million from IDHIFA royalties. Compared with the second quarter of 2019, total revenue grew 42%, driven by TIBSOVO sales climbing 101%, which was partially offset by a decline in collaboration revenue. As we mentioned in June, Royalty Pharma acquired our tiered, sales-based royalty rights tied to worldwide net sales of IDHIFA, along with the rights to collect as much as $55 million in outstanding ex U.S. We also received $255 million in regulatory milestone payments from BMS. With the debt method, this deal means we have to put a liability on our balance sheet equal to the purchase price minus issuance costs. Over the course of the arrangement, we'll continue to record the IDHIFA royalty. On top of that, we'll record noncash interest expense that's tied to the liability. In each period, the royalty revenue we record brings the liability down, while the noncash interest expense pushes it up. So whenever interest expense exceeds royalty, the liability rises. And when royalty revenue exceeds interest expense, the liability falls. Eventually the liability hits 0, and at that point we're no longer entitled to royalties under the 2010 agreement. On the call, we noted TIBSOVO's revenue increased $4.9 million compared with Q1 2020. That gain came from sustained, robust unit demand, along with channel inventory returning to levels closer to normal than where things stood when Q1 ended. Gross to net for the quarter fell inside the range we had anticipated, though Medicaid and PHS utilization climbed during the first half of the year, and we anticipate that pattern will persist through the rest of the year. Cost of sales came in at $675,000 for the quarter. Turning to operating expenses: R&D reached $90.9 million in the second quarter, a decline of $16.5 million relative to the second quarter of 2019. When you look at R&D, the drop from a year ago mostly came from a few things. Collaboration costs were lower — in the second quarter of 2019 we had $6 million in milestone payments tied to AG-636 and to an undisclosed early stage research program. We also saw the ClarIDHy Phase III study of TIBSOVO winding down, along with HOVON startup costs that we took on in Q2 2019. On top of that, spending on the TIBSOVO clinical studies still running fell, because enrollment slowed and activities were scaled back as a result of the COVID-19 pandemic. Turning to the second quarter, SG&A was $36 million, which is $3.6 million more than what we recorded in the same quarter of 2019. The primary factor here was the first stage of gated infrastructure construction for our European Union business, which was partially counterbalanced by reduced travel and industry engagement throughout our commercial team, a reflection of the measures put in place to combat the COVID-19 pandemic. At quarter's end, we held $794 million across cash, cash equivalents and marketable securities, and that total includes what we received through the Royalty Pharma agreement. Our closing cash position for Q2, combined with anticipated product revenue — though excluding expected program-specific milestone payments — is now projected to support our existing operating plan, which covers pivotal programs from mitapivat in thalassemia and sickle cell disease, all the way through the close of 2022. With that said, operator, please open the line for questions.

Alethia Young

analyst
#6

Nice work on everything you got done during the quarter. I suppose what I'd like to ask about is mitapivat in peds, and whatever detail you're able to share regarding the schedule and your intentions for advancing it. You mentioned that you're pushing ahead, I realize, but any additional information on that front would be useful.

Chris Bowden

executive
#7

Alethia, this is Chris. I missed that — an update on which program are you asking about?

Alethia Young

analyst
#8

Turning to mitapivat for pediatric patients. Is my audio coming through at this point?

Chris Bowden

executive
#9

Alright. Yeah, yeah, yeah. My issue was simply that I missed the portion about peds. Correct. So, our intention is to launch a study in pyruvate kinase deficiency during the coming year. Working out the protocol with Europe — that piece is essential, since it's a requirement you must satisfy before submitting for an adult indication, and afterward you're bound by a commitment you cannot deviate from — this negotiation consumes time, and we're currently in the middle of it. Still, we expect that study to begin in 2021. As for our pediatric development efforts in thalassemia and sickle cell, those strategies are not yet finalized.

Alethia Young

analyst
#10

Apologies — what I was asking about was PKR within the pediatric setting, something along those lines...

Chris Bowden

executive
#11

Right. So our aim is to launch a study in kids who have pyruvate kinase deficiency during the coming year. Beyond that, we'll pursue pediatric work as well involving mitapivat for thalassemia and sickle cell. As things stand, though, those intentions still need to be worked out.

Anupam Rama

analyst
#12

Congratulations on everything that's been accomplished. I wanted to ask something broader regarding sickle cell, specifically about mitapivat. Since EHA, one thing we keep hearing is: when you step back, what levers create differentiation — whether that means competing PKR activators or established options such as GBT?

Chris Bowden

executive
#13

Anupam, Chris speaking. I'll take the first pass, and others might chime in afterward. For mitapivat, I believe you're really evaluating 2 things — raising hemoglobin among patients whose anemia stems from their disease, plus episodes of acute chest syndrome, pain crises, and similar events, which represent a genuine unmet need. Our early development results out of the NIH study point to the best case being that we could impact both. On the competitor PKR activator front, it ultimately comes down to several considerations: we hold more than 4 years of mitapivat data, and a follow-on molecule is nearly ready to enter the clinic. We've accumulated substantial knowledge and led the way in mapping the biology, the translational science, and the clinical science. As more data appear, I think that will become clearer. The safety and efficacy profile matters greatly when patients receive a drug over extended periods. Another possibility, depending on how many new drugs reach the market, is that targeted therapies might be used together — that's further out on the horizon. Lastly, you raised how any of these drugs fit alongside Oxbryta. That product holds accelerated approval, and so far it has demonstrated hemoglobin increases adequate for that accelerated approval in roughly 50% of patients. Stepping back for a moment — it failed to show any statistically significant improvement in reducing VOCs. So taking that step back, when you consider the potential Oxbryta population, at least half of those individuals won't achieve an adequate response, which identifies a patient population right there for you.

Darrin Miles

executive
#14

Darrin here. Perhaps I could tack on a further thought to what Chris presented — I believe the key points came from him. When it comes to depreciation within the class, I mean, at the end of the day, data will be what decides it. What works in our favor is the depth and breadth of experience across our patient population, correct, since we'll have 1, 2 indications, even so — and the product is going to feel very familiar to treaters before any other potential rival in the class reaches the market. So I think that contributes substantially to boosting awareness, linearity, and comfort with mitapivat compared with other products.

Bruce Car

executive
#15

Bruce Car here, and I'll just build on that point. A key element when it comes to differentiation within the class is how distinctive the mechanism of action is for the allosteric PKR activators. As we make the cells healthier, we raise the ATP content. That means more cellular energy, and by bringing 2,3-DPG down, we make hemoglobin bind oxygen more tightly, directly. That works alongside the approaches that raise hemoglobin, such as hydroxyurea and similar agents. Our view is that in the end these mechanisms will complement one another, and may even be synergistic, once they're used together, which is something others have hinted at.

Tyler Van Buren

analyst
#16

I'd like to follow up on the mitapivat sickle cell program specifically. You said enrollment had been halted, yet it should resume this summer — by my reading, roughly a month from now — and that the eventual target is 25 patients, although it's unclear how many beyond 9 you can enroll ahead of ASH. Could you say more about that? What gives you confidence that it will reopen fairly soon this summer? And then perhaps outline how much time patients must spend on study for you to exceed that figure of 9 in time for ASH?

Chris Bowden

executive
#17

Yeah, Tyler — Chris here. What makes us think the study will start back up is largely based on what the NIH and Dr. Thein's team have been telling us: they anticipate the center reopening in the next few weeks. As for the second half of your question — what the data flow looks like after that — it really depends on the number of patients they're able to get consent from, enroll, and get clearance to treat. That could come down to — I'm not sure if the NIH will — my sense is they'll reopen in stages. So really, the volume of patients who can come in is going to be a matter of administration. To sum up the process: individuals arrive, complete initial assessments, receive therapy for a duration of eight weeks, must gradually reduce the medication, and afterward discontinue it. As for the number of subjects that might be included in any ASH abstract, that truly depends on when sites begin enrolling, how soon during the rest of the summer they start, and how many participants they are able to sign up. Factor in the eight-week treatment period plus the tapering phase, and naturally they require additional time to compile everything so it can be finalized for a December presentation. So it's very, very early. The good news is they seem quite sure the site will be up and running within a week or two, which we find encouraging. Dr. Thein is making arrangements so that patients will be ready to come in, and by now they've gained some familiarity with the drug. So we're hoping for the best that a handful of additional patients can be enrolled. Still, we're certain that at the very least, we'll have the specifics on those 8 patients we discussed during the EHA meeting.

Peter Lawson

analyst
#18

Regarding TIBSOVO's revenue and the count of distinct prescribers — could you discuss any effect COVID has had, and is there anything you can share about off-label usage?

Darrin Miles

executive
#19

Absolutely. This is Darrin speaking; up to now we have not managed to identify a meaningful COVID-related effect; new prescriptions and refills have grown nicely, and both keep trending favorably. As we mentioned, we experienced a substantial increase in first-time prescribers across academic and community practices alike. Yet the quickest expansion is in fact happening within the community setting, which is also heartening. There are, however, a few COVID-linked risks, correct? So in the end, we have not observed it yet, but there could potentially be some consequence when it comes to the initial diagnosis of AML patients. Even though this is a treatment-emergent illness, patients' unwillingness to come in might eventually become apparent. But so far we have not seen that to any notable degree. Ongoing work-from-home constraints affecting the sales force may introduce additional pressure; yet what we have also observed is a rise in Medicaid and 340B utilization, and we would anticipate that continuing, as Andrew said previously. And as for spontaneous adoption, off-label use in other settings — since, as we have stated on many occasions, our visibility into utilization for indications beyond AML is limited, but we do possess anecdotes about such uses.

Kennen MacKay

analyst
#20

Perhaps I was simply looking for you to go into a bit more detail regarding sickle cell and the genuine, pressing necessity for tapering — really for any drug employed to help raise how many red blood cells are circulating, particularly when it works through a change in the oxygenation curve of red blood cells and the oxygen binding curve. In that context, I believe that point may still be somewhat underappreciated.

Chris Bowden

executive
#21

Kennen, this is Chris speaking. So your question concerned tapering?

Kennen MacKay

analyst
#22

Apologies, regarding stopping the drug. Yes, let's return to a few of those safety events observed in sickle cell.

Chris Bowden

executive
#23

Yes. So, what we found with mitapivat in pyruvate kinase deficiency is that the optimal approach — the best-case scenario when a patient is going to discontinue the drug — is to reduce it step by step. And when you consider it, you have a drug that binds and stabilizes pyruvate kinase in the context of pyruvate kinase deficiency and then activates it across all these diseases, so halting it suddenly could cause hemoglobin to fall faster than if you wean it, and with a swift drop the patient is able to adjust quickly — is unable to adjust as well as when you do a gradual wean; so that's really the origin of that. Now, regarding — one point that I think arises is that people worry about compliance, given the statements and data suggesting noncompliance might be a bigger concern in sickle cell compared with other diseases. Based on what we know about the pharmacokinetics and the biology of the molecule, we don't believe that occasionally skipping a dose is likely to be an issue; but I think the recommendation that in the ideal situation, you want to steer clear of suddenly discontinuing the drug and instead have a taper is likely to be there. I would add that this holds true for many drugs, whether in hematology or other fields where you're doing chronic dosing.

Kennen MacKay

analyst
#24

And when it comes to the competition in this area — at least from one perspective, one of the ways mitapivat works is somewhat similar to Oxbryta's mechanism, in that it alters oxygen affinity along the partial pressure curve. Could you talk a little about whether these agents could theoretically be combined, and whether that's a realistic idea or one that wouldn't make sense? Also, congratulations on the progress made during Q2.

Chris Bowden

executive
#25

Yes. Well, I'd say combinability is of interest to us not only in sickle cell but also in thalassemia as new products emerge; and I think that comes down to mechanisms of action being complementary. So, to start with a thalassemia example — Take something like luspatercept, which boosts terminal erythroid differentiation — wouldn't there at least be a theoretical rationale that pushing more cells into that late stage could make them more responsive to the drug? That's definitely something worth exploring. Recent papers in the sickle cell field have been pointing to this — a wave of new agents arriving that seem to hold genuine promise for working in combination. When it comes to mitapivat and Oxbryta specifically, it's a fascinating question: if you can raise someone by 1 gram using Oxbryta, or 1.5 grams, would they gain anything from another 1.5 grams by layering on PKR wild-type activation through mitapivat? On one hand, that idea has real appeal. Conversely, you've likely been told by sickle cell specialists that they tend to be more cautious when it comes to modifying hemoglobin levels in these individuals. So absolutely, there's interest here, and not only for Oxbryta — other therapies down the road could benefit too, like a Novartis P-selectin inhibitor and similar agents. But speaking for ourselves, drawing on the sickle cell data we've generated so far, the preliminary findings we presented at ASH — at EHA — plus what we observe in thalassemia and our extensive history with mitapivat in pyruvate kinase deficiency, I'd say I'm genuinely enthusiastic about evaluating this drug on its own. My reasoning is that we may be able to accomplish two things at once: target both aspects of the disease and calm that overactive bone marrow that's straining so hard to compensate for the anemia. There's a chance we could also show that patients experience improvement in how they feel. So when it comes to combinations, the answer is yes — though we believe there's solid reason to expect that we can deliver a benefit to patients from a single agent on its own.

Bruce Car

executive
#26

Continuing along those lines, Chris — what patients report about outcomes has been positive, quite positive in anecdotal reports for the therapies we offer involving mitapivat throughout the indication. That picture doesn't hold for Oxbryta, even though it won approval for raising hemoglobin. What also matters is that Oxbryta binds covalently to hemoglobin, which stops the sickling — a genuinely significant point — yet it simultaneously reduces hemoglobin's capacity to transport oxygen, and that carries real weight. By contrast, we can keep hemoglobin inside healthier red blood cells, allowing them to transport more oxygen, with a stronger affinity for oxygen binding; therefore, in our view, our mechanism is actually better than the one Oxbryta relies on.

Hiroshi Shibutani

analyst
#27

There are three questions, all centered on mitapivat. Regarding mitapivat, you previously gave us an update on the PEAK registry and how patients are being identified. Is there anything new on that front? You also mentioned that timelines were being tightened according to how easily trial sites could be reached in order to obtain the ACTIVATE data that was under assessment. Obviously, a meeting had to happen 3 months ago. I'm simply wondering whether, so far, your impression is that things have moved faster than anticipated or turned out to be harder. Any detail you can offer about where that progress stands? I'm aware you told us the first half would be the window. Second, on sickle cell disease, there's this partnership with the NIH. Could you remind us what optionality exists and whether any plans are in place for clinical work in this indication that wouldn't involve the NIH? Or does a contract tie you to them? Please clarify, because my understanding is that much of the data sharing hinges on choices made together, and knowing whether you could independently steer trials and activities would be useful to us.

Chris Bowden

executive
#28

All right. This is Chris Bowden speaking. PEAK is operational in numerous nations globally; enrollment is going nicely. One thing we'd like to accomplish is taking the natural history study and being able to combine those findings with PEAK. That's an effort currently underway. The database comes from Boston Children's Hospital, so merging it — or bringing it together, extracting it and running the analysis is something we're keen to pursue and expect to discuss further down the road. So — and we believe it will serve as a significant — an enduringly significant data set allowing us to characterize burden-of-disease outcomes and the differences in how treatment is approached. We look forward to beginning to get that published and hope to be able to point people toward it; as for the difficulties and the fluctuations of clinical development during a worldwide pandemic, which I mentioned in my remarks, I cannot discuss particular locations or particular sites. But take a step back briefly and consider how the pandemic has shut down the United States as it spread from the East Coast and the West Coast, down to the south and around and up, there's considerable unpredictability involved. And based on how shut down a given hospital is and how they handle clinical trials along with their clinical research personnel and the reality that once they halt and later resume, a backlog forms, those are the kinds of elements we're examining while attempting to figure out how we'll get in there and retrieve our data, and that explains why no further guidance can be given right now. What I can say, though, is that we've performed well when it comes to keeping patients on the drug and gathering data through all the methods I mentioned earlier in my prepared remarks. We'll simply need to observe how matters unfold before we're able to give more definitive guidance — that's the reason we chose not to update it during this call. Now, regarding the NIH and questions about how we opt to conduct development, no restrictions apply to us. That is, after all, a CRADA agreement with them covering a trial. The data was shared by us openly. In fact, a number of the assays being run with Bruce's group are ones we're carrying out ourselves, so we retain freedom to operate, and we're proceeding quickly to launch a sickle cell trial during 2021, and none of that hinges in any way on an approval from the NIH or, for that matter — and our relationship with them is quite good, allowing us to talk through and lay out that data and bring it before health authorities whenever needed.

Jacqualyn Fouse

executive
#29

This is Jackie, and I'd like to step in briefly. There's a point Chris made that I believe deserves repeating. Regarding the ACTIVATE and ACTIVATE-T trials, there are 2 things you likely ought to consider. The first is data integrity — that's what Chris was referring to when he described how well our team has performed in keeping patients on the drug and making sure the trial, that they complete their trial experiences without problems and consistent with the protocol. The second is the timing around when we can put that out, or have it available, run the analysis, and then release the top line data. So in my view, data integrity matters enormously. If we rushed the data out and there were compromises to it, that would be a more serious problem than putting data integrity first and then dealing with when that top line data comes out. And as Chris mentioned, we feel good about it — about what the team has done in support of data integrity, and we haven't yet narrowed the timing window, since we still have a bit of distance to cover before getting into the sites and seeing that. And then, Chris, I think part of what your first question covered was the patient-finding efforts as well. At present, combining our clinical programs with our patient-finding efforts, we've got roughly 2,000 patients identified. Thank you.

Mohit Bansal

analyst
#30

James here, filling in for Mohit. I wanted to ask about AG-270. A different company just put out an announcement about a collaboration looking into MAT2A alongside PRMT1, and they shared some preclinical results indicating better potency and solubility than 270. Are you aware of that data? And how do you view their MAT2A program, plus the chance of combining it with PRMT1?

Bruce Car

executive
#31

Bruce Car speaking. I think the molecule from Ideo is what you mean. Right, when it comes to this pathway's capacity to reduce S-adenosylmethionine, pairing it with PRMT1 makes complete sense, and in our view PRMT5 might also be a potential participant here.

Michael Schmidt

analyst
#32

I had 2 additional questions about sickle cell, plus one regarding TIBSOVO. Perhaps this is somewhat of a follow-up to an earlier question about the Phase I NIH data. I was simply curious whether there might be any further details available concerning that single patient who had a VOC event. As I recall, at that point it was categorized as possibly related to treatment, though clearly VOCs happen frequently among patients in general. I'm just wondering, Chris, whether any updated information has emerged about that particular event that you could share?

Chris Bowden

executive
#33

Nothing new. That VOC took place during the taper. While patients were receiving active treatment, we observed no events at all. You're completely correct that this is an unfortunate aspect of the disease, and it's one we're working to address — namely, the VOCs. Throughout the taper, across those 8 patients who managed to finish either 6 or 8 weeks of dosing, we saw no further ones. No — so no new information, and it's something we'll keep monitoring. And given our overall impression of that data that we discussed at ASH, I think we clearly achieved proof of concept, and we're excited to move forward.

Michael Schmidt

analyst
#34

Great. And so you brought up, I believe, a meeting with the FDA where you talked over strategies for regulatory studies or approval — pivotal studies. And with the possible differentiation that came up before, I'm curious how you plan to make the most of that when designing your study. For instance, what do you think about going after an accelerated approval route, like GBT did, using Hb increase, or maybe including clinical outcomes like VOC reductions? How are you weighing those kinds of considerations?

Chris Bowden

executive
#35

Yes, that's the biggest thing our team is focused on right now — assembling a clinical development plan that can get us to approval, whether accelerated or regular, in the United States as well as in other regions outside the U.S; and the fascinating aspect of mitapivat is that we could potentially — we definitely have the ability to target hemoglobin. We showed that early, and we now understand that turning on wild-type PKR is a key approach across chronic hemoglobinopathies in general, chiefly thalassemia and sickle cell, as we've shown so far. We believe we have a chance to lower VOC; so then — so what, nothing I'm saying here is new. What's intriguing is how you put those together, plus possibly patient-reported outcomes, into a package that gets you there as fast as possible while also delivering the biggest benefit to patients. So we're working hard on that, and we're eager to have those conversations with both agencies as quickly as we can. Another thing we want to do is gather input from patients and patient advocates, since I believe that will significantly shape the kind of data that we're — that will matter to patients and really push them to use the drug; so many factors are at play. I know that accelerated approval built on hemoglobin increase has been shown with Oxbryta; and that's something we're examining very closely. But we think there's far more for us to consider given mitapivat's mechanism of action and the unmet need overall.

Michael Schmidt

analyst
#36

All right, that's helpful. Then I have a commercial question regarding TIBSOVO. I'm just wondering whether you might be able to tell us where market share stands right now, both in frontline and in relapsed/refractory AML, because it looks like growth has occurred in each. So I'd just like to know the current market share. In addition, I'm curious whether any use in cholangio has already shown up following the recent NCCN listing.

Darrin Miles

executive
#37

Certainly. This is Darrin. Because of the size of that population and how much visibility we have into utilization, I cannot provide precise penetration figures broken out by line of therapy. What I do have comes from physician reflections gathered through market research, along with how they use the drug by setting. So an exact penetration figure isn't something I can give you. However, what I can see is how utilization has shifted, as physicians describe it, over time. That is the basis on which I make comments about greater adoption across different settings. And what has been observed is ongoing adoption and ongoing improvement — or, rather, greater adoption — in the frontline setting, plus a solid spike in the relapse setting too. Actually, during the most recent quarter, we have seen more use of this product combined with HMA as well. As for utilization in cholangio, yes, we have heard — we have had anecdotes about use in the cholangio setting too. And with the recent NCCN guidelines, continued adoption there would not come as a surprise to us either.

Mark Breidenbach

analyst
#38

Nice work on the continued momentum. Perhaps one more mitapivat question, building off something Kennen asked. You sounded fairly unconcerned about a possible rebound effect in sickle cell patients who skip their dose for a day or 2. I'm curious what underpins that confidence. Also, why does no drug taper seem needed for patients taking Oxbryta? Any thoughts on how they manage without tapering would be really useful.

Chris Bowden

executive
#39

Why — this is Chris. Our belief that skipping a dose or 2 occasionally isn't a problem comes from what we observe — what we understand regarding how the drug binds to the enzyme and stays attached, and from what we understand when you examine findings from our healthy volunteer study, for instance, in which we measured 2,3-DPG and ATP levels once patients ceased dosing; those levels actually remained elevated across several days. So I'd say that's part of the evidence giving us confidence this won't become an issue where you skip a dose and abruptly you hit some kind of withdrawal problem. Then the other part of your — oh, right, why no taper is required. Well, they — Bruce might want to weigh in there. But something interesting: if you review a few of their Phase I and II datasets, you'll notice VOCs showing up as patients were discontinuing drug. They simply haven't linked those to drug, and investigators consider them unrelated to drug. That's really all I can offer on that. And I believe the key point for us when it comes to standing apart from Oxbryta will be, first, the proportion of patients responding to mitapivat versus Oxbryta, assuming both are on the market; the overall activity against VOCs, whether we can show that or not and whether, with longer follow-up, they will be able to; plus other dimensions of how patients feel better on these drugs. And I think — as I said earlier — if we can raise hemoglobin and tackle VOCs with a pill taken twice a day, that — we see a fairly compelling rationale for use.

Bruce Car

executive
#40

Yeah, and I'd just add to that, Chris — because mitapivat's pharmacodynamic effect lasts such a long time, a single skipped dose within the VOC schedule isn't going to be an issue. Oxbryta and mitapivat work through mechanisms that differ substantially. As I said earlier, Oxbryta binds covalently to the valine at the end of sickle hemoglobin, and that binding is permanent — that's what covalent binding means. It stays in place for the whole lifespan of the hemoglobin, and in hemoglobin bound to Oxbryta that lifespan exceeds 30 days. That may be one explanation.

Gobind Singh

analyst
#41

Gobind Singh from BMO Capital Markets here, filling in for George. Along the same lines as the earlier colleagues who posed questions: regarding that VOC patient, if my memory serves, the titration — the taper schedule — runs 12 days. So maybe you could weigh in on whether that VOC patient's event occurred in the back half of those 12 days, and whether that's the source of your confidence that skipping one dose is likely not going to be meaningful? Then, if I recall correctly, you folks said 2 patients had received doses under the 100-milligram protocol just before the COVID-19 shutdown took place. I was curious whether you've observed any hemoglobin responses in those patients, since it appears there's quite a pronounced dose-response relationship, so it wouldn't surprise me if the increases were larger there.

Chris Bowden

executive
#42

The patient who had the VOC did, in fact, experience it nearer the conclusion of the taper rather than the start. Qualitatively, I'd say that aligns with what you just heard from Bruce and me regarding the capacity to tolerate — without untoward effects — missing 1 or 2 or multiple doses of mitapivat. At EHA, what we discussed was that we presented data showing 7 of the 8 patients treated in that trial had a hemoglobin increase, and 5 of 8 had a rise exceeding 1 gram. That held across every cohort. We chose not to give individual data because we're reserving that for the ASH presentation, so as to give that presentation maximum power for a strong slide at the meeting. So your question is an excellent one — going from 50 milligrams to 100 milligrams or 200 milligrams, what exists there and how extensive is that dose-response relationship, whether we're talking hemoglobin or effect on oxygen dissociation curves. That's something we'll examine. It would be premature. As I said, I can't speak to the hundreds versus the patients who only reached 50. And it's a limited patient count, so we'll want to see more patients as we consider the dose question in sickle cell. I'll remind you that in thalassemia, in that protocol, we moved from 50 to 100. And we observed some modest hints that a slightly greater bump may appear going from 50 to 100; whether the same thing happens, or something different, in sickle cell remains to be seen. What we've learned regarding mitapivat, I believe, really comes back to the reason you constantly hear me discuss the drug's safety: we now have an understanding of the safety profile spanning many years, based on extension dosing within the DRIVE PK study. Beyond that, we're aware there's a spectrum of doses that tend to be tolerated quite well and are appropriate for development. I also think the subtleties of PKR when considered against each individual disease mean a possibility exists. There could be a variety of doses that physicians will want to consider as they weigh maximizing efficacy against safety. So — having spent several years working with this drug and reviewing the safety profile, I feel a great deal of comfort; thus, it's a very intriguing question. All we require is additional data, yet we know a range exists in which this drug can be dosed, and it tends to be tolerated quite well.

Jacqualyn Fouse

executive
#43

Thanks, operator. And thanks to everyone for being with us on this morning's call. I want to say again that even with the difficulties and unknowns in front of all of us, my excitement about what Agios has accomplished in our focus areas during the year so far has not diminished at all. Before I finish, I'd like to express my gratitude to the amazing people at Agios for the commitment and enthusiasm they bring to improving life for our patients, especially amid this uncertain moment around the globe. My thanks also go out to every patient, caregiver and physician taking part in our clinical trials. We simply could not do what we do without them. Thanks once more for being here today. We can't wait to see you and hear from you soon. Take care.

Operator

operator
#44

Everyone, that brings us to the end of today's conference call. We appreciate you joining in. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.